The FDA on January 28, 2016 approved HALAVEN® for the treatment of patients with unresectable or metastatic Liposarcoma who have received a prior Anthracycline-containing regimen. HALAVEN® is a product of Eisai Co., Ltd.
Top Ad
Advertisement
Advertisement
The FDA on January 28, 2016 approved HALAVEN® for the treatment of patients with unresectable or metastatic Liposarcoma who have received a prior Anthracycline-containing regimen. HALAVEN® is a product of Eisai Co., Ltd.